News
EDIT
6.16
+13.44%
0.73
Weekly Report: what happened at EDIT last week (0603-0607)?
Weekly Report · 2d ago
Weekly Report: what happened at EDIT last week (0527-0531)?
Weekly Report · 06/03 09:12
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Editas Medicine is a clinical-stage genome editing company. The company is developing a proprietary CRISPR/Cas9 technology to develop treatments for serious diseases. 4 analysts have shared their insights on Editas Medicine in the last three months. The analysts have set 12-month price targets for the company of $.
Benzinga · 05/30 16:00
Editas Medicine Price Target Cut to $7.00/Share From $15.00 by Evercore ISI Group
Dow Jones · 05/30 15:24
Editas Medicine Is Maintained at In-Line by Evercore ISI Group
Dow Jones · 05/30 15:24
Evercore ISI Group Maintains In-Line on Editas Medicine, Lowers Price Target to $7
Benzinga · 05/30 15:14
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
Zillow has carved out a niche in the online real estate marketplace. Editas Medicine is one of the most promising plays in the field of genomic medicine. Concentrix is leveraging the power of AI to improve its customer experience. Experts predict the second-half of the year will be a good time to buy undervalued stocks.
Investorplace · 05/30 13:49
EDITAS MEDICINE INC <EDIT.O>: EVERCORE ISI CUTS TARGET PRICE TO $7 FROM $15
Reuters · 05/30 13:16
U.S. RESEARCH ROUNDUP-Elevance Health, Wesco International, WW Grainger
Wall Street securities analysts revise their ratings and price targets on several companies. Elevance Health, Wesco International and WW Grainger among the companies. Cigna Group raises target price to $435 from $432. Advance Auto Parts, American Airlines and Airbnb among companies with target price cuts.
Reuters · 05/30 06:57
Weekly Report: what happened at EDIT last week (0520-0524)?
Weekly Report · 05/27 09:12
Weekly Report: what happened at EDIT last week (0513-0517)?
Weekly Report · 05/20 09:11
Editas Medicine: Promising Milestone Achieved But Be Patient
Seeking Alpha · 05/15 12:58
Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June
Editas Medicine to present clinical data from RUBY and EdiTHAL trials of renizgamglogene autogedtemcel at European Hematology Association Hybrid Congress in 2024. The company is a clinical-stage gene editing company. Two abstracts will be presented at the EHA Hybrid Congress.
Benzinga · 05/14 14:10
Weekly Report: what happened at EDIT last week (0506-0510)?
Weekly Report · 05/13 09:11
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
Editas Medicine, Inc. Reported disappointing quarterly earnings last week. Revenues of US$ missed forecasts by 84%. The company's per-share losses are expected to explode, reaching US$ per share in 2024. The company is expected to perform substantially worse than the wider industry. We look at the most recent consensus estimates for the company.
Simply Wall St · 05/12 12:16
Editas Medicine Reports Presentation Of Preclinical Data Demonstrating Several In Vivo Capabilities Towards Developing Transformative In Vivo Gene Editing Medicines
Benzinga · 05/10 10:06
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
TipRanks · 05/10 05:41
Editas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal Prudence
TipRanks · 05/10 05:32
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Barchart · 05/10 05:00
Editas Medicine Is Maintained at Buy by Citigroup
Dow Jones · 05/09 18:15
More
Webull provides a variety of real-time EDIT stock news. You can receive the latest news about Editas Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).